173 related articles for article (PubMed ID: 11708435)
1. Arthritis following recombinant outer surface protein A vaccination for Lyme disease.
Rosé CD; Fawcett PT; Gibney KM
J Rheumatol; 2001 Nov; 28(11):2555-7. PubMed ID: 11708435
[TBL] [Abstract][Full Text] [Related]
2. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
Molloy PJ; Berardi VP; Persing DH; Sigal LH
Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
[TBL] [Abstract][Full Text] [Related]
3. Lyme vaccine demonized by advocacy groups.
McSweegan E
Nature; 2006 Mar; 440(7082):278. PubMed ID: 16541048
[No Abstract] [Full Text] [Related]
4. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
Beran J; De Clercq N; Dieussaert I; Van Hoecke C
Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months.
Schoen RT; Sikand VK; Caldwell MC; Van Hoecke C; Gillet M; Buscarino C; Parenti DL
Clin Ther; 2000 Mar; 22(3):315-25. PubMed ID: 10963286
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial.
Sikand VK; Halsey N; Krause PJ; Sood SK; Geller R; Van Hoecke C; Buscarino C; Parenti D;
Pediatrics; 2001 Jul; 108(1):123-8. PubMed ID: 11433064
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
Wressnigg N; Pöllabauer EM; Aichinger G; Portsmouth D; Löw-Baselli A; Fritsch S; Livey I; Crowe BA; Schwendinger M; Brühl P; Pilz A; Dvorak T; Singer J; Firth C; Luft B; Schmitt B; Zeitlinger M; Müller M; Kollaritsch H; Paulke-Korinek M; Esen M; Kremsner PG; Ehrlich HJ; Barrett PN
Lancet Infect Dis; 2013 Aug; 13(8):680-9. PubMed ID: 23665341
[TBL] [Abstract][Full Text] [Related]
8. Outer surface protein A and arthritis in hamsters.
Parenti DL
Infect Immun; 2000 Dec; 68(12):7212-3. PubMed ID: 11203324
[No Abstract] [Full Text] [Related]
9. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
[TBL] [Abstract][Full Text] [Related]
11. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA.
Ding W; Huang X; Yang X; Dunn JJ; Luft BJ; Koide S; Lawson CL
J Mol Biol; 2000 Oct; 302(5):1153-64. PubMed ID: 11183781
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune mechanisms in antibiotic treatment-resistant lyme arthritis.
Steere AC; Gross D; Meyer AL; Huber BT
J Autoimmun; 2001 May; 16(3):263-8. PubMed ID: 11334491
[TBL] [Abstract][Full Text] [Related]
13. A novel multivalent OspA vaccine against Lyme borreliosis shows promise in Phase I/II studies.
Barrett PN; Portsmouth D
Expert Rev Vaccines; 2013 Sep; 12(9):973-5. PubMed ID: 24053389
[No Abstract] [Full Text] [Related]
14. Association of antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant epitopes of outer surface protein A of Borrelia burgdorferi.
Chen J; Field JA; Glickstein L; Molloy PJ; Huber BT; Steere AC
Arthritis Rheum; 1999 Sep; 42(9):1813-22. PubMed ID: 10513794
[TBL] [Abstract][Full Text] [Related]
15. The need for a new vaccine against lyme borreliosis.
Barrett PN; Portsmouth D
Expert Rev Vaccines; 2013 Feb; 12(2):101-3. PubMed ID: 23414400
[No Abstract] [Full Text] [Related]
16. Lyme disease and the Lyme disease vaccines.
Sigal LH
Bull Rheum Dis; 1999 Apr; 48(4):1-4. PubMed ID: 10418202
[TBL] [Abstract][Full Text] [Related]
17. Lyme disease vaccination: safety first.
Stricker RB; Johnson L
Lancet Infect Dis; 2014 Jan; 14(1):12. PubMed ID: 24355028
[No Abstract] [Full Text] [Related]
18. Lyme disease vaccination: are we ready to try again?
Lantos PM
Lancet Infect Dis; 2013 Aug; 13(8):643-4. PubMed ID: 23665340
[No Abstract] [Full Text] [Related]
19. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula.
Nassal M; Skamel C; Kratz PA; Wallich R; Stehle T; Simon MM
Eur J Immunol; 2005 Feb; 35(2):655-65. PubMed ID: 15668917
[TBL] [Abstract][Full Text] [Related]
20. Lyme disease vaccination: safety first - authors' reply.
Barrett PN; Crowe BA; Wressnigg N; Portsmouth D; Aichinger G
Lancet Infect Dis; 2014 Jan; 14(1):12-13. PubMed ID: 24355029
[No Abstract] [Full Text] [Related]
[Next] [New Search]
